If you have held Geron Corporation shares continuously since prior to February 28, 2024 you may have standing to hold Geron harmless from the alleged harm caused by the Company’s officers and directors by making them personally responsible. You may also be able to assist in reforming the Company’s corporate governance to prevent future wrongdoing. To learn more, contact Johnson Fistel, PLLP at jimb@johnsonfistel.com or (619) 814-4471.
Complaint Allegations
The Complaint alleges that Defendants provided these overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Rytelo’s potential; notably, that the lack of awareness for Rytelo, the burden of the continued monitoring requirement, and the impacts of seasonality and existing competition resulted in an inability for Geron to capitalize on the purportedly significant unmet need for the drug, particularly among first-line patients and those outside the academic setting.